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DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is the key regulator of the non-homologous end
joining pathway of DNA double-strand break repair. We have previously reported that DNA-PKcs is required for
maintaining chromosomal stability and mitosis progression. Our further investigations reveal that deficiency in
DNA-PKcs activity caused a delay in mitotic entry due to dysregulation of cyclin-dependent kinase 1 (Cdk1), the key
driving force for cell cycle progression through G2/M transition. Timely activation of Cdk1 requires polo-like kinase
1 (Plk1), which affects modulators of Cdk1. We found that DNA-PKcs physically interacts with Plk1 and could
facilitate Plk1 activation both in vitro and in vivo. Further, DNA-PKcs–deficient cells are highly sensitive to Plk1
inhibitor BI2536, suggesting that the coordination between DNA-PKcs and Plk1 is not only crucial to ensure normal
cell cycle progression through G2/M phases but also required for cellular resistance to mitotic stress. On the basis
of the current study, it is predictable that combined inhibition of DNA-PKcs and Plk1 can be employed in cancer
therapy strategy for synthetic lethality.
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DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a key
component of the non-homologous end joining pathway, plays a pivotal
role in DNA double-strand break repair [1]. In addition, DNA-PKcs is
critical for normal cell cycle progression through mitosis as cells lacking a
functional DNA-PKcs display a delay in mitotic transition and increases
in abnormal spindle formation and chromosomal instability [2,3].
Although the precisemechanism leading tomitoticDNA-PKcs activation
remains to be clarified, recent evidence indicates that DNA-PKcs
activation stimulates the Chk2-Brca1 signaling pathway in mitosis to
facilitate microtubule dynamics regulation [3].
Cell cycle progression from the G2 phase to mitosis is tightly regulated
through a mitosis-promoting factor complex consisting of Cdk1 and
cyclin B1 [4]. Accumulation of cyclin B1 before mitotic entry promotes
the formation of the Cdk1–cyclin B1 complex [5,6]. However, Cdk1 is
kept in the inactive status by Wee1 and Myt1 kinase through inhibitory
phosphorylation of Cdk1 [7,8]. The dual-specific phosphatase Cdc25C is
required to remove the inhibitory phosphorylation of Cdk1 and tofacilitate Cdk1 activation [9]. The activated Cdk1–cyclin B1 complex
then accumulates in the nucleus and triggers chromosome condensation
and nuclear envelop breakdown [10].
Polo-like kinase 1 (Plk1) is also a key mitotic regulator and is
crucial for multiple processes throughout mitosis transition until
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domain and a C-terminal polo box domain (PBD), which recognizes
phospho-serine or phospho-threonine sequences and is crucial for
Plk1 association with its substrates [12,13]. For example, several Plk1
docking partners are phosphorylated by Cdk1 during mitosis to
facilitate Plk1 recruitment and subsequent Plk1-dependent phos-
phorylations [14]. Conversely, Plk1 could regulate Cdk1 activity
through multiple mechanisms. First, Plk1-dependent phosphoryla-
tion activates Cdc25C and its nuclear translocation [15]. Plk1 also
phosphorylates Wee1 and promotes its degradation through β-TrCP–
dependent ubiquitination [16,17]. Additionally, Plk1 could phos-
phorylate cyclin B1 to stimulate Cdk1–cyclin B1 at the centrosome
and promote its nuclear import [18,19].
The current study further reveals that DNA-PKcs is involved in the
timely activation of Cdk1 and mitotic entry through Plk1.
DNA-PKcs directly interacts with Plk1 and could stimulate its
kinase activity in vitro and in vivo. Our findings demonstrate that the
crosstalk between DNA-PKcs and Plk1 plays a vital role in cellular
progression and survival through mitosis.
Materials and Methods
Cell Culture, Synchrony, and Small Inhibitory RNATransfection
All cell cultures, including human cervical cancer HeLa cells,
human colon cancer HCT116 and derivative DNA-PKcs−/− cells
[20], and Ligase 4−/− [21], were maintained in α-minimum essential
medium supplemented with 10% FBS. Mitosis synchronization was
performed as described previously [2]. Small inhibitory RNA
(siRNA) oligonucleotides designed against DNA-PKcs [22] were
transfected with RNAiMax (Invitrogen, Carlsbad, CA).
Immunoblot Analysis and Antibodies
Whole-cell lysate preparation and Western blot analysis were
performed as described [23,24]. Phospho-specific anti–DNA-PKcs
antibodies were described previously [23–25]. Antibodies used in this
study include anti-Cdk1, anti–phospho-Cdk1 (pY15), anti-Cdc25C,
anti-Wee1, anti-Myt1, anti–cyclin B1, anti–poly(ADP-ribose) poly-
merase 1 (PARP-1) (Cell Signaling Technology, Danvers, MA), anti–
phospho-histone H3 (pH3), anti–cyclin A (Upstate), anti-Plk1
(Bethyl Laboratories, Montgomery, TX), and anti–β-actin (Sigma-
Aldrich, St. Louis, MO) and were commercially available as indicated.
Flow Cytometry Analysis
Flow cytometry analysis was performed as described [26]. In brief,
harvested cells were fixed in 70% ethanol, washed with phosphate-
buffered saline, and incubated in propidium iodide (PI) solution (0.1
mg/ml RNase A, 0.1% Triton X-100, and 20 mg/ml PI in
phosphate-buffered saline) for 30 minutes at 37°C. DNA content was
measured by an FS500 flow cytometer, and cell cycle compartments
were analyzed using the CXP cytometry analysis program (Beckman
Coulter, Brea, CA). For mitotic indicator pH3 analysis, cells were
incubated with anti-pH3 for 1 hour followed by fluorescein
isothiocyanate–conjugated secondary antibody for 1 hour. Mitotic
cell population was analyzed with the CXP cytometry analysis program.
Mitotic index analysis was performed as previously described [2].
Immunoprecipitation and Glutathione S-Transferase Pull-
Down Assays
For immunoprecipitation (IP), cells were lysed in lysis buffer
[50 mM Tris HCl (pH 7.5), 150 mM NaCl, 1% Tween 20, 0.5%NP-40, and protease inhibitor cocktail]. Cell lysates were incubated
with 2 μg of control IgG or indicated specific antibodies at 4°C
overnight, incubated with protein A/G agarose beads (Roche,
Branford, CT) for 1 hour, followed by three washes in IP buffer
and two washes in kinase reaction buffer (IP-kinase assay only, see
below). For glutathione S-transferase (GST) pull-down assay, GST–
DNA-PKcs fusion proteins were incubated with glutathione-sephar-
ose beads (GE Healthcare Life Sciences, Piscataway, NJ) and then
recombinant Plk1 proteins followed by immunoblot analysis.
Protein Purification and In Vitro Kinase Assays
DNA-PKcs and Ku proteins were purified as described before
[27]. Recombinant His-tagged wild-type and kinase dead (KD) Plk1
proteins were prepared from a bacterial expression system and
purified through Ni-NTA agarose (Qiagen, Valencia, CA) and
Superdex200 and MonoQ 5/50 column chromatography (GE
Healthcare Life Sciences). In vitro DNA-PKcs kinase assay was
performed as described elsewhere [27]. For in vitro Plk1 kinase assay,
purified recombinant Plk1 or immunoprecipitated endogenous Plk1
proteins were incubated in Plk1 kinase reaction buffer [20 mM
HEPES (pH 7.4), 100 mM KCl, 10 mM MgCl2, 1 mM EDTA,
0.5 mMDTT, 5% glycerol, 10 μMATP, and 0.17 μM γ-32P ATP]
with recombinant GST-Cdc25C or casein (Sigma) as substrates. The
reaction was incubated at 30°C for 30 minutes and stopped by
adding sodium dodecyl sulfate (SDS) sample buffer. In the combined
DNA-PKcs and Plk1 kinase reaction, Plk1 kinase buffer was used.
After kinase reaction, samples were subject to SDS–polyacrylamide
gel electrophoresis analysis. Incorporation of 32P was analyzed by
Typhoon 9410 Imager (GE Healthcare Life Sciences).
Clonogenic Survival Assay
Clonogenic survival assay was performed as described elsewhere
[23]. In brief, cells were plated onto 60-mm culture dishes followed
by incubation with Plk1 inhibitor BI2536 for 7 to 10 days. Cells were
fixed and stained with crystal violet. Colonies containing more than
50 cells were scored under a microscope.
Results
DNA-PKcs Is Required for Cell Cycle Progression into Mitosis
We have previously reported that DNA-PKcs is a critical regulator
of mitosis progression and chromosomal stability maintenance [2,3].
Here, we further investigate whether DNA-PKcs is required for cell
cycle progression into mitosis. HeLa cells transfected with either
siRNA against DNA-PKcs or control siRNA were subjected to
microtubule destabilizer nocodazole. Nocodazole treatment caused a
dramatic increase in mitotic index in control HeLa cells but not in
DNA-PKcs knockdown HeLa cells. In comparison, greater than
75.5 ± 10.0% of control cells were arrested in mitosis at 16 hours,
whereas only 37.3 ± 1.8% of DNA-PKcs knockdown cells entered
into mitosis (Figure 1A). A similar result was generated when control
and DNA-PKcs knockdown cells were subjected to flow cytometry
analysis using pH3 as a mitotic indicator (Figure 1B). At 16 hours
after nocodazole treatment, a G2 population in DNA-PKcs
knockdown cells remained, whereas most control cells entered into
mitosis and were positively stained with pH3. We also observed that,
in the absence of nocodazole, there was a slight increase in mitotic
index in DNA-PKcs knockdown HeLa cells. This increase in mitotic
index is likely due to a defect in chromosome segregation,
Figure 1. DNA-PKcs is required for cell cycle progression into mitosis. (A) HeLa cells were transfected with control siRNA or DNA-PKcs
siRNA for 48 hours and were incubated with nocodazole (50 ng/ml) for the indicated time. After harvest, cells were processed for
chromosome spread and mitotic index analysis. The result was generated from three independent experiments. ***P b .001. (B) The
harvested HeLa cells were analyzed by flow cytometry against anti-pH3 antibody and PI staining. (C) Human colon cancer HCT116 cells
and derivative DNA-PKcs knockout cells (PKcs−/−), DNA Ligase IV knockout cells (Lig4−/−), as well as PKcs−/− cells complemented with
wild-type DNA-PKcs (PKcs+) were treated with nocodazole. Mitotic index were analyzed as described.
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knockdown cells [2].
To further validate the role of DNA-PKcs in mitotic entry, human
colon cancer HCT116 and the derivative DNA-PKcs knockout
(DNA-PKcs−/−) cells were analyzed for nocodazole-induced mitotic
indices. Consistent with DNA-PKcs knockdown HeLa cells,
DNA-PKcs−/− cells displayed decreased mitotic indices than the
parental HCT116 cells in response to nocodazole treatment
(Figure 1C). This reduction was rescued by restoration of DNA-PKcsexpression in DNA-PKcs−/− cells (PKcs+) and was not observed in
DNA Ligase IV knockout (Lig4−/−) HCT116 cells. These results
underscore a distinct role of DNA-PKcs to facilitate mitotic entry
independently of its function in non-homologous end joining or
DNA double-strand break repair.
DNA-PKcs Deficiency Delays Cdk1 Activation and G2/M Transition
Cell cycle progression from the G2 phase entering into mitosis is
primarily governed the cyclin-dependent kinase 1 (Cdk1). Cdk1
332 DNA-PKcs facilitates Plk1 activation and mitotic entry Lee et al. Neoplasia Vol. 17, No. 4, 2015activation requires its complex with cyclin B1 and removal of Cdk1
inhibitory phosphorylation at Tyr15 (pY15). We further examined
whether DNA-PKcs depletion alters Cdk1 activation during G2/M
transition. Nocodazole synchrony caused a transient increase in Cdk1
pY15 in control HeLa cells before mitotic entry followed by removal
of Cdk1 pY15 at later time points (Figure 2A), when the majority of
cells have already entered into mitosis (Figure 1). The levels of Cdk1
pY15, however, were higher in DNA-PKcs knockdown HeLa cells
before and after nocodazole treatment even at later time points.
Dysregulation of Cdk1 pY15 was also found in DNA-PKcs−/− cells.
Similar to DNA-PKcs knockdown in HeLa cells, the overall levels of
Cdk1 pY15 were significantly elevated in DNA-PKcs−/− cells
compared to the parental wild-type HCT116 cells (Figure 2B).
Contrary to the change in Cdk1 pY15 expression, Cdk1 total protein
levels remained constant in control and DNA-PKcs–deficient cells at
various time points.
The timely expression of Cdk1 pY15 is regulated through the
balance between Wee1-type kinases [7,8] and Cdc25C phosphatase
[9]. Consistent with the elevation of Cdk1 pY15 in DNA-PKcs–
defective cells, we observed that activation of Cdc25C phosphatase, asA
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cells stably expressing shGFP or shATM were incubated with nocodindicated by its hyperphosphorylation [28], was significantly
attenuated in DNA-PKcs–depleted HeLa cells (Figure 2A). Addi-
tionally, we observed that DNA-PKcs is involved in the timely
inactivation of Wee1 and Myt1 kinases. Nocodazole treatment
caused a transient increase in Wee1 and Myt1 protein levels in
HCT116 cells at 6 hours followed by their depletion at later time
points when cells entered into mitosis, whereas increased expression
levels of Wee1 and Myt1 were found in DNA-PKcs−/− cells
(Figure 2B), suggesting that mitosis-specific degradation of Wee1
and Myt1 was significantly delayed in the absence of DNA-PKcs
(Figure 2B). To further determine whether DNA-PKcs kinase activity
is involved in mitosis entrance, thymidine-synchronized HeLa cells
were released into the S phase and were subjected to DNA-PKcs
inhibitor Nu7441 incubation. We observed that there is a delay in
Cdk1 phosphorylation as well as histone H3 Ser10 phosphorylation
(Figure 2C), indicating that DNA-PKcs kinase activity is involved in
mitosis transition.
It has been documented that DNA-PKcs is required for the
optimal expression of ataxia telangiectasia mutated (ATM) [29,30]. It
is possible that the reduction of ATM expression in DNA-PKcs–B
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entrance. To determine this possibility, HeLa cells expressing
shRNA against ATM (shATM) or green fluorescent protein
(shGFP) were subjected to nocodazole treatment and were analyzed
for mitotic markers. As shown in Figure 2D, both shATM and shGFP
cells displayed similar kinetics of Cdk1 and Cdc25C phosphoryla-
tions as well as cyclin B1 accumulation. These results suggest that
expression levels of ATM are not critical for mitotic entrance.
DNA-PKcs Interacts with Plk1
Impaired Cdc25C phosphorylation and Wee1 degradation have
been reported in cells with defective Plk1 activity [15–17]. Thus, we
speculated that DNA-PKcs might have a functional link with Plk1.
This notion is further supported by our previous report that
mitosis-specific indication of DNA-PKcs phosphorylation overlaps
with Plk1 at centrosomes, kinetochores, and mid-body during mitosis
[2]. To test this hypothesis, asynchronous and nocodazole-treated
HeLa cell lysates were subjected to IP with anti–DNA-PKcs or
anti-Plk1 antibodies. Our analysis revealed that Plk1 and DNA-PKcs
could be reciprocally co-immunoprecipitated and that their complex
formation increased in mitosis-synchronized cells (Figure 3A). The
interaction between DNA-PKcs and Plk1 was also detected fromA
B
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Figure 3. DNA-PKcs directly interacts with Plk1. (A) Sham or
nocodazole (50 ng/ml, 16 hours) treated HeLa cell lysates were
immunoprecipitated using anti-Plk1 or anti–DNA-PKcs antibodies.
Immunoprecipitated proteins were analyzed by immunoblot
analysis to determine the association between DNA-PKcs and
Plk1. (B) Domain mapping of direct protein-protein interaction
between DNA-PKcs and Plk1. GST fusion proteins carrying
different regions of DNA-PKcs (bottom panel, stained by Ponceau
S) were incubated with His-tagged full-length Plk1 or Plk1 PBD
domain followed by glutathione agarose pull-down. The bound
Plk1 or PBD domain was detected by anti-His antibody. Numbers
on the top indicate the coverage of DNA-PKcs residues in each GST
fusion protein.overexpression of flag-tagged Plk1 in 293 cells that DNA-PKcs
preferentially interacts with Plk1 than the Ku70/80 complex in the
absence of DNA damage (Supplementary Figure 1). To further
investigate whether there is direct protein-protein interaction between
DNA-PKcs and Plk1, full-length recombinant Plk1 was expressed
and purified from Escherichia coli (Supplementary Figure 2) and was
subjected to GST pull-down assay using a series of GST fusions
carrying different fragments of DNA-PKcs. GST pull-down assay
revealed that full-length Plk1 preferentially binds to both 1878-2182
and 2261-2700 regions of DNA-PKcs covering Ser2056 and the
Thr2609 phosphorylation cluster, respectively (Figure 3B). GST
pull-down was further investigated using the C-terminal PBD of
Plk1. Plk1 PBD also interacted with DNA-PKcs at the same regions
with stronger affinity to the 2261-2700 fragment (Figure 3B).
DNA-PKcs Promotes Plk1 Activation
The direct protein-protein interaction between DNA-PKcs and
Plk1 kinases prompted us to speculate that DNA-PKcs could
modulate Plk1 activity. To test this hypothesis, recombinant Plk1 was
subjected to in vitro kinase reaction together with the endogenously
purified DNA-PK protein complex from HeLa cells. The DNA-PK
kinase, consisting of DNA-PKcs and Ku70/80 heterodimer, was
kinase active and further stimulated in the presence of DNA
(Figure 4A, lanes 4-5 with Xrcc4 as substrate). Recombinant
wild-type Plk1 was also kinase active alone and could autopho-
sphorylate itself under the in vitro kinase reaction (lane 1). Such Plk1
phosphorylation was significantly enhanced in the presence of active
DNA-PK kinase (lane 6). Conversely, we observed that the level of
DNA-PKcs phosphorylation increased in the presence of Plk1 (lane 5
vs lane 6), which is consistent with recent report that Plk1
phosphorylates DNA-PKcs [31]. It is possible that DNA-PKcs and
Plk1 association stimulates Plk1 kinase and autophosphorylation
in vitro, or DNA-PKcs could play a direct role and phosphorylate
Plk1 in vitro. To delineate the mechanism, recombinant KD mutant
Plk1 was examined in in vitro kinase assay. Plk1 KD mutant was
unable to phosphorylate by itself alone (lane 2) but was phosphor-
ylated by the DNA-PK kinase (lane 7). Further analysis revealed that
DNA-PKcs could directly phosphorylate the C-terminal PBD
domain of Plk1 (lane 8). To determine whether DNA-PKcs could
stimulate Plk1 kinase activity in vitro, Plk1 activity was further
examined with recombinant Cdc25C as substrate (Figure 4B). Our
analyses revealed that Plk1 could phosphorylate Cdc25C in vitro
(lane 3) and the levels of Cdc25C phosphorylation slightly enhanced
in the presence of Ku or DNA-PKcs alone (lanes 5 and 6,
respectively). However, in the presence of the active DNA-PK kinase
(lane 8), Plk1-mediated Cdc25C phosphorylation decreased, which
was contrary to a significant increase in Plk1 and DNA-PKcs
phosphorylation. These results suggest that DNA-PKcs and Plk1
association mutually stimulates each other in vitro. It is possible that
DNA-PKcs and Plk1 are preferable substrates of each other.
To validate the in vitro result generated with recombinant Plk1,
endogenously expressed Plk1 was immunoprecipitated from HeLa
cells for evaluation of its kinase activity. Our analysis revealed that
immunoprecipitated Plk1 could phosphorylate Cdc25C and that
Plk1-mediated Cdc25C phosphorylation was attenuated in the
presence of Plk1 inhibitor BI2536 but not DNA-PKcs inhibitor
NU7441 (Figure 4C). Similarly, NU7441 incubation did not alter
the kinase activity of recombinant Plk1 in vitro (Supplementary
Figure 3). However, when HeLa cells were pretreated with NU7441
AB
1 2 3 4 5 6 7 8
DNA-PKcs
Plk1
PBD
Xrcc4
WT KD PBD - -
- - - + + - - -
- - - - + + + + DNA
Xrcc4
Plk1
- - - + + + + + DNA-PK
WT KD PBD
Noc- +
HCT116 PKcs-/-
Plk1 pT210
- +
Plk1
C
D
E
Plk1 
32P-Cdc25C
Cdc25C
loading
IgG αPlk1
- NU
Plk1
GST-Cdc25
Plk1
GST-Cdc25
Ku80
DNA-PKcs
1 2 3 4 5 6 7 8
- + + + + + + +
- - - - - + - + DNA-PKcs
Cdc25C
Plk1
- - - - + - + + Ku
+ - + + + + + +
- - - + - - + + DNA
-
IgG αPlk1
NU BI
32P-Cde25C
Plk1 
Cdc25C
loading
Figure 4. DNA-PKcs stimulates Plk1 kinase activity in vitro and in vivo. (A) Recombinant His-tagged wild-type Plk1, KD mutant, and PBD
domain were subjected to in vitro kinase reactions in the presence or absence of HeLa-purified DNA-PK complex. C-terminal fragment of
XRCC4 was included as a positive control of DNA-PK kinase activity. (B) Similar in vitro kinase reactions were performed with recombinant
GST-Cdc25C as Plk1 substrate. The bottom panel shows the loadings of recombinant Plk1 and GST-Cdc25C. The amounts of DNA-PKcs and
Ku proteins were not sufficient to be visualized by Coomassie blue staining. (C) Endogenous Plk1 proteins were immunoprecipitated with
control IgG or α-Plk1 antibodies from HeLa cell extracts and were subjected to kinase reaction in the presence of γ-32P ATP, purified
GST-Cdc25C (substrate), and inhibitors against DNA-PKcs or Plk1 (NU7441 and BI2536, respectively, 10 μM). Immunoblot analysis of Plk1
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compared to that of sham retreated HeLa cells (Figure 4D).
Furthermore, we observed that mitotic induction of Plk1 phosphor-
ylation at Thr210 was significantly decreased in DNA-PKcs−/− cells
compared to that in the parental HCT116 cells (Figure 4E). Taken
together, these results indicate that the kinase activity of DNA-PKcs is
required for optimal Plk1 activation in vivo.
Combined Inhibition of DNA-PKcs and Plk1 Results in
Synthetic Lethality
The coordination between DNA-PKcs and Plk1 is likely critical for
cell cycle progression through G2/M transition, various steps in mitosis,
as well as cellular resistance against mitotic stress. We also expect that
DNA-PKcs–deficient cells will be susceptible on Plk1 inhibition. Totest this hypothesis, HCT116 andDNA-PKcs−/− cells were treatedwith
Plk1 kinase inhibitor BI2536 and were analyzed for mitotic index.
Overnight incubation with BI2536 at 10 nM concentration induced
significant mitotic arrest in DNA-PKcs−/− cells but only mild mitotic
arrest in HCT116 cells as measured by pH3 in flow cytometry analysis
and immunofluorescence staining (Figure 5A). In addition, we observed
that BI2536 treatment induced a sub-G1 population (representing cells
undergo apoptosis) in DNA-PKcs−/− cells but not in HCT116 cells
(Figure 5B). BI2536-induced apoptosis was also evidenced by cleavage
of PARP-1 in immunoblot analysis. The result showed that BI2536
treatment resulted in severe PARP-1 cleavage and apoptosis in
DNA-PKcs−/− cells but not in HCT116 cells (Figure 5C).
Susceptibility of DNA-PKcs−/− cells toward BI2536 was further
determined using the clonogenic survival assay. Our analysis revealed
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the parental HCT116 cells (Figure 6A). This result also suggested that
combined inhibition of both DNA-PKcs and Plk1 kinases could
achieve synthetic lethality with potential implication in cancer
treatment. To test this possibility, DNA-PKcs–proficient HCT116
cells were subjected to increasing concentrations of BI2536 alone or
were treated in conjunction with specific DNA-PKcs kinase inhibitor
NU7441. As expected, NU7441 treatment further augmented the
cell killing effect of BI2536 in clonogenic survival assay (Figure 6B) as
well as in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) cell viability assay (Supplementary Figure 4). These
results indeed support the therapeutic potential to target DNA-PKcs
and Plk1 kinases simultaneously for achieving combined modality in
cancer treatment.Discussion
In the current study, we reveal that DNA-PKcs plays a crucial role in
cell cycle progression through the G2/M transition. Depletion orA
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multiple processes throughout the entire course of mitosis [32]. Our
results further demonstrate that there is a direct association between
DNA-PKcs and Plk1 in mitosis (Figure 3) and that DNA-PKcs could
stimulate Plk1 activation both in vitro and in vivo (Figure 4). Thus,
in the absence of a functional DNA-PKcs, inadequate Plk1 activation
fails to support the timely activation of Cdk1 kinase and results in
delay of mitotic entry. Consistent with this notion, our results also
demonstrate that DNA-PKcs–defective cells are sensitive to Plk1
kinase inhibitor BI2536. Taken together, these results demonstrate
that the interaction between DNA-PKcs and Plk1 facilitates the
optimal activation of Plk1 and is required for timely mitotic entry as
well as cellular resistance to mitotic stress.
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336 DNA-PKcs facilitates Plk1 activation and mitotic entry Lee et al. Neoplasia Vol. 17, No. 4, 2015DNA-PKcs autophosphorylation is associated with spindle apparatus
and completely overlaps with mitotic Plk1 at centrosomes,
kinetochores, and mid-body [2]. These results also imply that there
are both functional and physical links between these two kinases.
Consistent with our report, the association between DNA-PKcs and
Plk1 has been verified recently by independent groups [31,33]. Here,
we further demonstrate that there is a direct protein-protein
interaction between PBD domain of Plk1 and fragments of
DNA-PKcs that cover two key phosphorylation regions, the
Thr2609 cluster and Ser2056 [23–25]. Crystallographic studies of
Plk1 reveal that the C-terminal PBD directly interacts with the
N-terminal kinase domain to block its own kinase activation [12,34].
Such auto-inhibition can be reversed through Plk1 phosphorylation
at Thr210 or through direct interaction between Plk1 PBD and Plk1
target proteins [35]. Although recent evidence suggested that
Aurora-A kinase can phosphorylate Plk1 at Thr210 and promote its
activation [36], it was initially reported that Plk1 can autopho-
sphorylate itself at the same residue [37]. Consistent with this notion,
our in vitro kinase assay showed that recombinant wild-type Plk1
could phosphorylate itself and that Plk1 phosphorylation was further
stimulated in the presence of DNA-PKcs. We speculate that the
association of Plk1 PBD with DNA-PKcs Thr2609 cluster or
Ser2056 regions may relieve the inhibitory effect of Plk1 PBD on its
kinase domain. Alternatively, it is possible that DNA-PKcs
phosphorylates Plk1 and alleviates the inhibitory effect of Plk1
PBD, which is supported by our observation that DNA-PKcs could
phosphorylate Plk1 KD mutant protein and the C-terminal PBD
fragment (Figure 4A). These two possible yet distinctive scenarios are
not mutually exclusive and could both contribute to DNA-PKcs–
dependent Plk1 activation.
The crosstalk between DNA-PKcs and Plk1 is unlikely to be
unidirectional as we observed that DNA-PKcs phosphorylation
in vitro was stimulated in the presence of an active Plk1 kinase
(Figure 4A), indicating that Plk1 could either phosphorylate
DNA-PKcs directly or stimulate DNA-PKcs autophosphorylation.
A recent study by Douglas et al. reported that Plk1 phosphorylates
DNA-PKcs at Ser3205 during mitosis and that mitotic DNA-PKcs
activation and phosphorylation occurs independent of Ku70/80
heterodimer [31]. This leads to a possible scenario that Plk1-mediated
DNA-PKcs phosphorylation at Ser3205 further enhances DNA-PKcskinase activation and results in Ku-independent DNA-PKcs
activation. However, treatment with Plk1 inhibitor BI2536 blocked
only Ser3205 phosphorylation, but it did not affect other DNA-PKcs
downstream phosphorylation events in mitosis. Douglas et al. further
reported that DNA-PKcs phosphorylation at Ser3205 is removed by
protein phosphatase 6 (PP6) as siRNA depletion of PP6 improves
Ser3205 phosphorylation in mitosis and after ionizing radiation (IR)
[31]. Independent studies have also reported that PP6 is a modulator
of DNA-PKcs and is required for IR-induced DNA-PKcs activation
and radioresistance [38,39]. Thus, further investigation will be
needed to delineate the impact of Plk1-dependent DNA-PKcs
phosphorylation and whether Plk1 directly modulates DNA-PKcs
activity in mitosis. Nonetheless, these data support our findings that
association between DNA-PKcs and Plk1 reciprocally affects both
kinases.
The coordination between DNA-PKcs and Plk1 is critical for
preserving chromosomal stability and completion of cell division. We
have previously reported that, in DNA-PKcs–defective cells, there is a
delay in mitotic progression and an increase in mitotic index due to
impairment in chromosome alignment and segregation [2,3]. Our
analyses further revealed that DNA-PKcs is involved in modulation of
microtubule dynamics and attachment to kinetochores through direct
regulation of the Chk2-Brca1 signaling pathway, which is known to
regulate mitotic spindle formation and maintenance of chromosomal
stability [40]. Similarly, Plk1 is also capable of modulating microtubule
nucleation and attachment to kinetochores through multiple down-
stream effector molecules [41–43]. It is unlikely that Plk1 could affect
DNA-PKcs downstream Chk2-Brca1 signaling since mitosis-induced
Chk2 phosphorylation was not affected by Plk1 inhibitor [31]. In
contrast, DNA-PKcs might influence Plk1 function in microtubule
dynamics as DNA-PKcs could facilitate Plk1 activation (Figure 4).
Further, DNA-PKcs–deficient cells are sensitivity toward the Plk1
inhibitor (Figure 6A). Their coordination is likely required for optimal
regulation of microtubule to ensure proper chromosome segregation
during mitosis and successful cell division.
Chromosome instability is one of the key hallmarks of cancer cells
and the driving force for carcinogenesis [44]. It is conceivable that an
elevation in either Plk1 or DNA-PKcs activity would promote
chromosome stability and/or mitigate the intrinsic chromosome
instability character in most cancer cells to support continuous cell
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development of various cancer types and correlates with poor patient
prognosis [45]. Evidence further indicates that Plk1 could contribute
to chemoresistance [46]. Thus, molecular targeting of Plk1 has
emerged as an attractive therapeutic strategy for a wide range of
cancers [12,47]. For example, BI2536 is a highly selective and potent
Plk1 inhibitor identified by a diverse organic compound screening
and had passed phase II clinical trials [48]. Similarly, a growing body
of evidence has implicated a role of DNA-PKcs in carcinogenesis and
development of radioresistance in tumor, and thus, various
anti-DNA-PKcs strategies have evolved [49]. Here, we further
investigate whether synthetic lethality can be achieved with
combination of both Plk1 and DNA-PKcs inhibitors in their
sublethal dosage. Consistent with this hypothesis, our result
demonstrated that combined inhibition of both DNA-PKcs and
Plk1 increased mitotic arrest and cellular apoptosis (Figure 5) and
reduced clonogenic survival ability (Figure 6). This combined
modality strategy could be beneficial in particularly targeting tumors
with elevated Plk1 or DNA-PKcs activities.
In conclusion, our works reveal that there is a direct association
between DNA-PKcs and Plk1 and that their coordination is required
for timely activation of Cdk1 kinase and normal cell cycle progression
through G2/M transition. Our results also shed new light on the
therapeutic potential of targeting both DNA-PKcs and Plk1 for
synthetic lethality in cancer treatment.
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